Helen E Heslop, MD, DSc (Hon)

Professor
Baylor College of Medicine

Helen E Heslop, MD, DSc (Hon) Photo

Positions

Professor
Departments of Medicine and Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine
Houston, TX US

Director - Center for Cell and Gene Therapy
Baylor College of Medicine
Houston, TX US

Dan L Duncan Chair
Baylor College of Medicine

Interim Director
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States

Leader, Cancer Cell & Gene Therapy
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States

Addresses

TX Childs Feigin Ctr (Work)
Room: TXFC-164006
Mail Stop: BCM320
Houston, Texas 77030
United States
(832) 824-4671
Google Maps
TX Childs Feigin Ctr (Office)
Room: TXFC-164006
Mail Stop: BCM320
Houston, Texas 77030
United States
(832) 824-4671
Google Maps
Houston Methodist Hospital (Clinic)
6565 Fannin St., Suite 800
Houston, Texas 77030
United States
(713) 394-6250
Google Maps
Houston Methodist Hospital (Hospital)
6565 Fannin St., Suite 800
Houston, Texas 77030
United States
(713) 394-6250
Google Maps

Certifications

  • Fellow of the Royal Australasian College of Physicians (FRACP)

  • Fellow of the Royal College of Pathologists of Australasia (FRCPA)

Education

  • M.D. from University Of Otago, New Zealand
    01/1990 - Otago New Zealand
  • Advanced Training from Royal Free Hospital
    01/1986 - London United Kingdom
  • Advanced Training from Christchurch Hospital
    01/1982 - Christchurch New Zealand
  • M.B.,Ch.B. from University Of Otago, New Zealand
    01/1980 - Otago New Zealand

Language

  • English

Gender

  • Female

Professional Statement

Helen Heslop is a physician-scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy. A key step in this strategy has been the translation of laboratory findings to Phase I and II clinical trials, as exemplified by studies of Epstein Barr virus-induced lymphoproliferative disease (EBV-LPD), a fatal complication in about 15% of recipients of unrelated or mismatched family member bone marrow transplants in the early 1990s. In collaboration with Dr Cliona Rooney, she developed methods for early diagnosis of this disease and procedures for generating cytotoxic T lymphocytes (CTLs) from bone marrow donors. These studies were the first to demonstrate that antigen-specific cytotoxic T cells could eradicate an established malignancy and because the cells were genetically marked, we obtained definitive evidence of cell expansion, trafficking to tumor sites and decade-long persistence. Subsequent protocols have extended this approach to Hodgkin's Disease, NHL and nasopharyngeal cancer. She has an additional focus in reconstituting antiviral immunity post transplant in collaboration with Drs. Rooney, Leen and Bollard and is currently leading an NHLBI-funded multicenter trial of allogeneic multivirus specific T cells. She therefore has extensive experience in developing and conducting transplant studies and cell and gene therapy studies under IND and has also obtained orphan drug designation for my initial study. Other areas of research focus in collaboration include identification of novel tumor antigens and genetic modification of CTLs to overcome tumor evasion strategies. In collaboration with Drs. Brenner, Dotti, Savoldo, Gottschalk and Ahded group they are also evaluating if transduction of CTLs with chimeric antigen receptors can allow targeting of CD19+ve, CD30+ve and her2neu+ve malignancies.

Professional Achievements

  • President
    01/2012 - Foundation for Accreditation Cell Therapy

Professional Interests

  • Cell and Gene Therapy

Professional Specialties

  • Hematology-Oncology

  • Blood and Marrow Transplantation